Recent advances revolutionize treatment of metastatic prostate cancer

Future Oncology

Volumn 9, Issue 8, 2013, Pages 1133-1144

  Madan, Ravi A ^a   Arlen, Philip M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

castration resistant; hormone therapy; immunotherapy; metastatic prostate cancer

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; ARN 509; BICALUTAMIDE; CABOZANTINIB; CORTICOTROPIN; CYTOCHROME P450 17; DOCETAXEL; ENZALUTAMIDE; FLUTAMIDE; IBRITUMOMAB TIUXETAN; IPILIMUMAB; NILUTAMIDE; ORTERONEL; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RADIUM CHLORIDE RA 223; RILIMOGENE GALVACIREPVEC; SAMARIUM 153; SIPULEUCEL T; STRONTIUM 89; TASQUINIMOD; UNCLASSIFIED DRUG;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CHILL; COLITIS; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEVER; FLUID RETENTION; HORMONAL THERAPY; HOT FLUSH; HUMAN; HYPERTENSION; HYPOKALEMIA; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; INJECTION SITE REACTION; LIVER FUNCTION TEST; METASTATIC MELANOMA; MUSCULOSKELETAL PAIN; NAUSEA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATE METASTASIS; RASH; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT RESPONSE; VOMITING;

ANDROSTENOLS; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE-FREE SURVIVAL; HORMONE REPLACEMENT THERAPY; HUMANS; IMMUNOTHERAPY; MALE; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS; TISSUE EXTRACTS;

EID: 84881294465     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.65     Document Type: Review

References (78)

1. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351 (15), 1502-1512 (2004).
2. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351 (15), 1513-1520 (2004).
3. Nelson JB, Fizazi K, Miller K et al. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer 118 (22), 5709-5718 (2012).
4. Kelly WK, Halabi S, Carducci M et al. Randomized, double-blind, placebo-controlled Phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J. Clin. Oncol. 30 (13), 1534-1540 (2012).
5. Scher HI, Jia X, Chi K et al. Randomized, open-label Phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J. Clin. Oncol. 29 (16), 2191-2198 (2011).
6. Aragon-Ching JB, Jain L, Gulley JL et al. Final analysis of a Phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int. 103 (12), 1636-1640 (2009).
7. Tannock I, Fizazi K, Ivanov S et al. Aflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): Results from the multinational Phase III trial (VENICE). J. Clin. Oncol. 31 (Suppl. 6), Abstract 13 (2013).
8. Araujo JC, Trudel GC, Saad F et al. Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized Phase III READY trial. J. Clin. Oncol. 31 (Suppl. 6), Abstract LBA8 (2013).
9. Michaelson MD, Oudard S, Ou Y et al. Randomized, placebo-controlled, Phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 29 (Suppl.), Abstract 4515 (2011).
10. De Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376 (9747), 1147-1154 (2010).
11. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 62 (1), 10-29 (2012).
12. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J. Clin. 22 (4), 232-240 (1972).
13. Kojima S, Suzuki H, Akakura K, Shimbo M, Ichikawa T, Ito H. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J. Urol. 171 (2 Pt 1), 679-683 (2004).
14. Kassouf W, Tanguay S, Aprikian AG. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J. Urol. 169 (5), 1742-1744 (2003).
15. Scher HI, Liebertz C, Kelly WK et al. Bicalutamide for advanced prostate cancer: The natural versus treated history of disease. J. Clin. Oncol. 15 (8), 2928-2938 (1997).
16. Ryan CJ, Smith MR, Fong L et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J. Clin. Oncol. 28 (9), 1481-1488 (2010).
17. Madan RA, Arlen PM. Abiraterone. Cougar biotechnology. IDrugs 9 (1), 49-55 (2006).
18. De Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364 (21), 1995-2005 (2011).
19. Fizazi K, Scher HI, Molina A et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled Phase 3 study. Lancet Oncol. 13 (10), 983-992 (2012).
20. Logothetis CJ, Basch E, Molina A et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: Exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol. 13 (12), 1210-1217 (2012).
21. Ryan CJ, Smith MR, De Bono JS et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368 (2), 138-148 (2013).
22. Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: New agents for an established target. Lancet Oncol. 10 (10), 981-991 (2009).
23. Sartor AO, Tangen CM, Hussain MH et al. Antiandrogen withdrawal in castrate-refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9426). Cancer 112 (11), 2393-2400 (2008).
24. Small EJ, Halabi S, Dawson NA et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A Phase III trial (CALGB 9583). J. Clin. Oncol. 22 (6), 1025-1033 (2004).
25. Scher HI, Beer TM, Higano CS et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: A Phase 1-2 study. Lancet 375 (9724), 1437-1446 (2010).
26. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367 (13), 1187-1197 (2012).
27. Sharifi N, Dahut WL, Steinberg SM et al. A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU Int. 96 (7), 985-989 (2005).
28. George DJ, Corn PG, Michaelson MD, Hammers HJ, Alumkal J. Safety and activity of the investigational agent orteronel (ortl) without prednisone in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA): Updated results of a Phase II study. J. Clin. Oncol. 30 (Suppl.), Abstract 4549 (2012).
29. Clegg NJ, Wongvipat J, Joseph JD et al. ARN-509: A novel antiandrogen for prostate cancer treatment. Cancer Res. 72 (6), 1494-1503 (2012).
30. Madan RA, Schwaab T, Gulley JL. Strategies for optimizing the clinical impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer. J. Natl Compr. Canc. Netw. 10 (12), 1505-1512 (2012).
31. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (17), 1591-1597 (1999).
32. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases. Cancer 82 (11), 2256-2261 (1998).
33. Goldfarb DA, Stein BS, Shamszadeh M, Petersen RO. Age-related changes in tissue levels of prostatic acid phosphatase and prostate specific antigen. J. Urol. 136 (6), 1266-1269 (1986).
34. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest. Urol. 17 (2), 159-163 (1979).
35. Chakraborty NG, Stevens RL, Mehrotra S et al. Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation. Cancer Immunol. Immunother. 52 (8), 497-505 (2003).
36. Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: Effects of docetaxel on immune enhancement. Clin. Cancer Res. 14 (11), 3536-3544 (2008).
37. Patel PH, Kockler DR. Sipuleucel-T: A vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Ann. Pharmacother. 42 (1), 91-98 (2008).
38. Rini BI. Technology evaluation: APC-8015, dendreon. Curr. Opin. Mol. Ther. 4 (1), 76-79 (2002).
39. Small EJ, Fratesi P, Reese DM et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 18 (23), 3894-3903 (2000).
40. Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24 (19), 3089-3094 (2006).
41. Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, double-blind, placebo-controlled, Phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115 (16), 3670-3679 (2009).
42. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363 (5), 411-422 (2010).
43. Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Prostvac-VF: A vector-based vaccine targeting PSA in prostate cancer. Expert Opin. Invest. Drugs 18 (7), 1001-1011 (2009).
44. Kantoff PW, Schuetz TJ, Blumenstein BA et al. Overall survival analysis of a Phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28 (7), 1099-1105 (2010).
45. Gulley JL, Arlen PM, Madan RA et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol. Immunother. 59 (5), 663-674 (2010).
46. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182 (2), 459-465 (1995).
47. Waterhouse P, Penninger JM, Timms E et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270 (5238), 985-988 (1995).
48. Pardoll D. Releasing the brakes on antitumor immune response. Science 271 (5256), 1691 (1996).
49. Hodi FS, O'Day SJ, Mcdermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363 (8), 711-723 (2010).
50. Chakraborty M, Abrams SI, Camphausen K et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J. Immunol. 170 (12), 6338-6347 (2003).
51. Postow MA, Callahan MK, Barker CA et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366 (10), 925-931 (2012).
52. Madan RA, Gulley JL, Fojo T, Dahut WL. Therapeutic cancer vaccines in prostate cancer: The paradox of improved survival without changes in time to progression. Oncologist 15 (9), 969-975 (2010).
53. Sheikh NA, Petrylak D, Kantoff PW et al. Sipuleucel-T immune parameters correlate with survival: An analysis of the randomized Phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol. Immunother. 62 (1), 137-147 (2013).
54. Huber ML, Haynes L, Parker C, Iversen P. Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J. Natl Cancer Inst. 104 (4), 273-279 (2012).
55. Kantoff PW, Higano CS, Small EJ, Whitmore JB, Frohlich MW, Schellhammer PF. Re: Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J. Natl Cancer Inst. 104 (14), 1107-1109; author reply 1109-1112 (2012).
56. Gulley JL, Leitman SF, Dahut W, Schlom J. Re: Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J. Natl Cancer Inst. 104 (14), 1106; author reply 1109-1112 (2012).
57. Drake CG. Re: Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J. Natl Cancer Inst. 104 (18), 1422; author reply 1422-1423 (2012).
58. Stein WD, Gulley JL, Schlom J et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: The growth rate constant as an indicator of therapeutic efficacy. Clin. Cancer Res. 17 (4), 907-917 (2011).
59. Madan RA, Bilusic M, Heery C, Schlom J, Gulley JL. Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Semin. Oncol. 39 (3), 296-304 (2012).
60. Dipaola RS, Chen Y, Bubley GJ et al. A Phase II study of PROSTVAC-V (vaccinia)/TRICOM and PROSTVAC-F (fowlpox)/TRICOM with GM-CSF in patients with PSA progression after local therapy for prostate cancer: Results of ECOG 9802. Presented at: 2009 Genitourinary Cancers Symposium. Orlando, FL, USA, 26-28 February 2009.
61. Beer TM, Bernstein GT, Corman JM et al. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin. Cancer Res. 17 (13), 4558-4567 (2011).
62. Sartor O, Reid RH, Hoskin PJ et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 63 (5), 940-945 (2004).
63. Zorga P, Birkenfeld B, Listewnik MH, Piwowarska-Bilska H. Effectiveness of strontium-89 palliative therapy in patients with painful bone metastases. Ann. Acad. Med. Stetin. 57 (1), 49-53; discussion 53 (2011).
64. Witzig TE, Gordon LI, Cabanillas F et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 20 (10), 2453-2463 (2002).
65. Nilsson S, Strang P, Aksnes AK et al. A randomized, dose-response, multicenter Phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur. J. Cancer 48 (5), 678-686 (2012).
66. Sartor AO, Heinrich D, Helle SI et al. Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: A Phase III randomized trial (ALSYMPCA). J. Clin. Oncol. 30 (Suppl. 5), Abstract 9 (2012).
67. Pisters LL, Troncoso P, Zhau HE, Li W, Von Eschenbach AC, Chung LW. c-met proto-oncogene expression in benign and malignant human prostate tissues. J. Urol. 154 (1), 293-298 (1995).
68. Borre M, Offersen BV, Nerstrom B, Overgaard J. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br. J. Cancer 78 (7), 940-944 (1998).
69. Michaelson MD, Oudard S, Ou Y, Sengelov L, Saad F, Houede N. Randomized, placebo-controlled, Phase III trial of sunitinib in combination with prednisone versus prednisone alone in men with progressive metastatic castration-resistant prostate cancer. J. Clin. Oncol. 29 (Suppl.), Abstract 4515 (2011).
70. Smith DC, Smith MR, Sweeney C et al. Cabozantinib in patients with advanced prostate cancer: Results of a Phase II randomized discontinuation trial. J. Clin. Oncol. 31 (4), 412-419 (2013).
71. Lee RJ, Michaelson MD, Saylor PJ, Gurski CA, Rothenberg SM. Investigator-sponsored trial of efficacy and tolerability of cabozantinib at lower dose: A dose-finding study in men with castration-resistant prostate cancer and bone metastases. J. Clin. Oncol. 30 (Suppl.), Abstract 4566 (2012).
72. Smith MR, Saad F, Coleman R et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a Phase 3, randomised, placebo-controlled trial. Lancet 379 (9810), 39-46 (2012).
73. Dalrymple SL, Becker RE, Isaacs JT. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts. Prostate 67 (7), 790-797 (2007).
74. Isaacs JT, Pili R, Qian DZ et al. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. Prostate 66 (16), 1768-1778 (2006).
75. Kallberg E, Vogl T, Liberg D et al. S100A9 interaction with TLR4 promotes tumor growth. PLoS One 7 (3), e34207 (2012).
76. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 8 (8), 618-631 (2008).
77. Bratt O, Haggman M, Ahlgren G, Nordle O, Bjork A, Damber JE. Open-label, clinical Phase I studies of tasquinimod in patients with castration-resistant prostate cancer. Br. J. Cancer 101 (8), 1233-1240 (2009).
78. Pili R, Haggman M, Stadler WM et al. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J. Clin. Oncol. 29 (30), 4022-4028 (2011).